➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
Colorcon
Baxter
Moodys

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

AVASTIN Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for AVASTIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Genentech, Inc.Early Phase 1
Massachusetts General HospitalEarly Phase 1
Azienda Unità Sanitaria Locale Reggio EmiliaPhase 3

See all AVASTIN clinical trials

Recent Litigation for AVASTIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Myriad Genetics, Inc.2020-12-20
Ravgen, Inc. v. Progenity, Inc.2020-12-20
Ravgen, Inc. v. Ariosa Diagnostics, Inc.2020-12-02

See all AVASTIN litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Pfizer Inc.2018-01-05
2017-12-20

See all AVASTIN litigation

Company Disclosures: US Patents for AVASTIN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Get Started Free Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Get Started Free Biogen, Inc. (Cambridge, MA) 2020-08-05 RX company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Get Started Free Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Get Started Free Biogen, Inc. (Cambridge, MA) 2020-08-05 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for AVASTIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for AVASTIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
92642 Luxembourg   Get Started Free PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805
122014000065 Germany   Get Started Free PRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
132014902271575 Italy   Get Started Free PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220
301056 Netherlands   Get Started Free PRODUCT NAME: POLATUZUMAB VEDOTIN; REGISTRATION NO/DATE: EU/1/19/1388 20200120
300673 Netherlands   Get Started Free PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
132006901471186 Italy   Get Started Free PRODUCT NAME: NATALIZUMAB(TYSABRI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/06/346/001, 20060627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Baxter
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.